Analytical Consequences of Potent Drugs

  • Hans de Bree
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 18 A)


Pharmaceutical companies having their own R & D organization are increasingly confronted with the severe demands of the registration authorities. Besides the proof of safety and efficacy a third criterion is developing: a new drug in a given therapeutic area must be better than existing ones, in respect of therapeutic effect, fewer or no side-effects, or both criteria. This trend has led to the development of a number of rather potent drugs, having low dose regimes. Besides the implications for departments involved in synthesis and pharmacology, there are consequences for other disciplines such as analysis.


Irritable Bowel Syndrome Amide Bond Determination Limit Peak Plasma Level Registration Authority 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



electron-capture detection


fluorobenzoic acid


pentafluorobenzyl (bromide)


internal standard


retention time


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ceelen, P.R.J., Ruijten, H.M. & de Bree, H. (1986) in Bioactive Analytes, including CNS Drugs, Peptides and Enantiomers [Vol. 16, this series] (Reid, E., Scales, B. & Wilson, I.D.), Plenum, N. York, p. 297.Google Scholar
  2. 2.
    Pearce, J.C., Jelly, J.A., Fernandes, K.A., Leavens, W.J. & McDowall, R.D. (1986) J. Chromatog. 353, 371–378.CrossRefGoogle Scholar
  3. 3.
    de Ridder, J.J., Koppens, P.C.J.M. & van Hal, H.J.M. (1977) J. Chromatog. 143, 281–287.Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Hans de Bree
    • 1
  1. 1.Analytical Development DepartmentDuphar Research LaboratoriesWeespThe Netherlands

Personalised recommendations